65,437 trials
Atopic Dermatitis
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Site Reactions — 88; 1; 15 Participants
Cataract
Primary: Mean Photopic Monocular Best Corrected Distance Visual Acuity (4 m) — -0.014; -0.039 logMAR
Breast Cancer · Pain, Postoperative · BRCA1 Mutation
Primary: Change From Baseline in Average Pain Scores Using a Numeric Pain Intensity Scale — 2; 3 score on a scale — p=0.43
Dermatomyositis
Primary: To Assess the Safety and Tolerability of IMO-8400 in Adult Subjects With DM — 6; 4; 2; 4 participants
Venous Insufficiency · Oedema · Varicose Veins
Primary: Venous Haemodynamics - Percent Change in Time Averaged Mean Velocity TAMV — 102.4; -9.1 percentage change — p=0.001
Peripheral T-cell Lymphoma
Primary: Complete Remission (CR) Rate — 3 Participants
Colitis, Ulcerative
Primary: Percentage of Participants Who Achieved Clinical Remission — 22.5; 31.3 percentage of participants — p=0.0061
Puberty
Primary: Pubertal Onset — 9.86; 9.86; 11.66; 11.66 years
COPD
Primary: Change From Baseline in Peak FEV1 on Day 3 — 0.565; 0.506; 0.519 Liters — p=0.168
Acne Vulgaris
Primary: Total Inflammatory Facial Lesion Count at Day 85 — 21.9; 20.3; 18.5 Lesions
HIV
Primary: Changes in Systemic Immune Activation From Baseline Observed by the CD69 Expression on CD4 T Cells — 4.04; 5.55; 4.9; 4.99 percentage of cells
Pregnancy
Primary: Delivery Times Measured in Partogram — 389.33; 561.3 minutes — p=0.776
Erythropoietic Protoporphyria
Primary: Cumulative Number of Days of Phototoxic Reactions (Study Efficacy Population) — 39; 45; 129; 179 Days
Liver Fibrosis · Hepatitis C · HIV
Primary: Percentage of Participants Experiencing Treatment-Emergent Adverse Events — 100; 100; 100 percentage of participants
Patients With Newly Diagnosed Glioblastoma
Primary: Summary of the Median Progression-free Survival (mPFS) in the Combined 800 mg, 5 Days/Week Dose Group — 6.7; 6.9 months